DDJ Clinical Article · As of March 2026
6-Month Recall: Evidence-Based Standard or Mostly Tradition?
Evidence supports risk-based recall intervals rather than a uniform 6-month default for every patient.
Critical Bias Points
- Fixed 6-month schedule vs. risk-based recall: For low-risk patients, the added benefit of a rigid 6-month interval is weak.
- Early detection and prevention vs. traditional service structure: A general standard based on habit alone is poorly supported.
- Patient selection: A one-size-fits-all rule obscures different baseline risks.
For Clinical Practice
- It is important to move away from routine formulas and toward interval-based logic.
- Recall must not be written as an inevitable law of care.
- It is important to explicitly state for whom closer monitoring is more likely to be beneficial.
Clinical Key Question
Is the 6-month recall an evidence-based standard or primarily mainly a long-standing routine?
The current evidence supports the clinical benefit. The effect is consistent across multiple independent reviews and is clinically relevant.
The benefit is substantially better supported than possible risks. The benefit literature is based on multiple high-quality systematic reviews.
The clinical assessment runs along 3 decision axes: fixed 6-month schedule vs. risk-based recall, early detection and prevention vs. traditional service structure, patient selection.
Executive Summary
Anyone who wants to read this topic rigorously must separate several levels. First: individualized risk adjustment is clinically more plausible than a universal standard. Second: at higher risk, closer monitoring may be appropriate. Third: a higher disease risk more readily justifies shorter intervals.
Public debate frequently goes off track at precisely this point. From individual study results, sweeping claims are made online that take neither methodological quality nor the specific context of application into account. This is scientifically unsound. But it would be equally wrong to reflexively dismiss every critical question. DDJ must accomplish both simultaneously: present the benefit robustly and keep open uncertainties visible.
For readability, this also means: this article is not a yes-or-no answer to a headline, but the resolution of a complex body of evidence. The clinical significance depends on the specific context, the patient population, and the goal of the decision. Only once these levels are separated does an emotionally charged debate become a clinically useful dental judgment.
Claim Clusters and Decision Axes
Claim Cluster 1
Fixed 6-Month Schedule vs. Risk-Based Recall
The central evidence on this question is provided by the fifth update of the Cochrane review on recall intervals (Fee et al. 2020). This analysis included for the first time, alongside the small Norwegian study by Wang (1992), the British INTERVAL trial, enabling analysis of data from a total of 1,736 participants. The comparison of risk-based recall intervals with conventional 6-month recall in adults over four years showed a mean difference of 0.15 tooth surfaces with caries (95% CI: −0.77 to 1.08; 1,478 participants; high certainty of evidence), a mean difference in gingival bleeding rate of 0.78 percentage points (95% CI: −1.17 to 2.73; 1,472 participants; high certainty of evidence), and an OHIP-14 difference of −0.35 points (95% CI: −1.02 to 0.32; 1,551 participants; high certainty of evidence). No clinically relevant difference was demonstrable in any of these endpoints.
Particularly noteworthy is the comparison of the extended 24-month interval with the 6-month standard. Here too, the INTERVAL trial showed no clinically meaningful difference in adults deemed suitable for an extended interval by their treating dentist: the mean difference in caries increment at tooth-surface level was −0.60 (95% CI: −2.54 to 1.34; 271 participants; moderate certainty of evidence), the bleeding rate differed by −0.91 percentage points (95% CI: −5.02 to 3.20; 271 participants; moderate certainty of evidence), and oral health-related quality of life was virtually identical (OHIP-14 difference: −0.24; 95% CI: −1.55 to 1.07; 305 participants; high certainty of evidence). This demonstrates that even doubling the interval to two years did not produce measurable deterioration in suitable patients.
The INTERVAL trial (Clarkson, Pitts et al.) forms the methodological backbone of this evidence. It was conducted as a pragmatic, multicenter RCT across 51 British dental practices and enrolled adult patients defined as regular dental attendees (at least one visit in the previous two years). Randomization was stratified: patients assessed by their dentist as suitable for a 24-month interval could be allocated to any of the three arms; patients with higher clinical risk could only be allocated to the risk-based or 6-month recall arms. Clinical endpoints were assessed after four years by blinded outcome assessors. The trial was powered at 80–90% to detect clinically relevant differences in gingival bleeding and quality of life.